Top Tweets for #AlloCART

5 months ago

Excited to attend Stanford’s BMT & CAR-T Symposium and learning from experts across the country. The symposium provided valuable insights into the current landscape and future developments in malignant hematology. #MaligHem #Lymphoma #MM #Leukemia #CART #ASCT #AlloCART #ORCA-T

drzarak's tweet photo. Excited to attend Stanford’s BMT & CAR-T Symposium and learning from experts across the country. The symposium provided valuable insights into the current landscape and future developments in malignant hematology.

#MaligHem #Lymphoma #MM #Leukemia #CART #ASCT #AlloCART #ORCA-T https://t.co/4Zoc83Vy3B

128

Patrick J. Hanley 🧬 @DrPHanley

about 2 years ago

Exciting news here for two reasons: 1. Renewed promise of #alloCART 2. Use or nonviral gene delivery which I think will be more prevalent very soon #cart #celltherapy H/T @markflower https://t.co/EhKKNKvZXg

652

John Connolly

@John_E_Connolly

over 3 years ago

Really interesting paper with implications for #allocart CD28-CAR-T cell activation through FYN kinase signaling rather than LCK enhances therapeutic performance: Cell Reports Medicine https://t.co/0xDYWyCeBB

Ankit kansagra

@kansagraMD

over 5 years ago

@ManniMD1 @bdermanmd I have pushed #CART studies to publish outcomes based on all pts enrolled in studies, not just who get pheresis. That is an imp piece i often see omited and with #bispecific and #AlloCART those no's are going to be crucial.

Anne-Pierre Pickaert @Care4Access

over 5 years ago

Preliminary lower activity of #AlloCART vs #autologous #CARTcells does not hamper the enthusiasm of Dr Adam Cohen @pennmedicine. Confirmatory data will show if #allogenous #celltherapy is a viable option for #relapsed #refractory #myelomapatients #CART21 @TheEBMT @EHA_Hematology

$Care4Access's tweet photo. Preliminary lower activity of #AlloCART vs #autologous #CARTcells does not hamper the enthusiasm of Dr Adam Cohen @pennmedicine. Confirmatory data will show if #allogenous #celltherapy is a viable option for #relapsed #refractory #myelomapatients #CART21 @TheEBMT @EHA_Hematology https://t.co/aYT3DwFYEQ$

Allogene Therapeutics @AllogeneTx

almost 6 years ago

Today we received clearance for our IND from the @US_FDA to study our BCMA-targeted #AlloCART #celltherapy in combination with @SpringWorksTx’s gamma secretase inhibitor in patients with relapsed/refractory multiple myeloma. Looking forward to initiating in Q1 2021. #mmsm $ALLO

Allogene Therapeutics @AllogeneTx

almost 6 years ago

To make CAR T more accessible to patients, we need to solve inherent limitations of autologous therapy. We believe #AlloCART therapy is the next-generation innovation with the potential to revolutionize the field of #celltherapy and #cancer treatment. https://t.co/t6DYPfB5c0

Allogene Therapeutics @AllogeneTx

about 6 years ago

#BREAKINGNEWS: Today we announced a strategic five-year collaboration with @MDAndersonNews for the preclinical and clinical investigation of #AlloCART candidates across Allogene’s broad portfolio of #hematologic and #solidtumors. https://t.co/mpa0o57a6l $ALLO

AllogeneTx's tweet photo. #BREAKINGNEWS: Today we announced a strategic five-year collaboration with @MDAndersonNews for the preclinical and clinical investigation of #AlloCART candidates across Allogene’s broad portfolio of #hematologic and #solidtumors. https://t.co/mpa0o57a6l $ALLO https://t.co/vxuzBCre3B

Allogene Therapeutics @AllogeneTx

about 6 years ago

One of the potential benefits of off-the-shelf #AlloCART therapies - like the elimination of certain logistical challenges with autologous CAR T therapies - has become more apparent during COVID-19. Learn more about off-the-shelf #celltherapy $ALLO

AllogeneTx's tweet photo. One of the potential benefits of off-the-shelf #AlloCART therapies - like the elimination of certain logistical challenges with autologous CAR T therapies - has become more apparent during COVID-19. Learn more about off-the-shelf #celltherapy $ALLO

Allogene Therapeutics @AllogeneTx

about 6 years ago

Allogene is leading today, creating tomorrow with the development of allogeneic #CAR_T therapy. Our #AlloCART therapies have the potential to overcome the limitations autologous therapies. Learn more: https://t.co/AIQshBz241 #immunotherapy $ALLO

Dr Victor Noriega @noriega_dr

over 6 years ago

W Qasim, #allocart as deep conditioning for 2nd allograft.

Top Tweets for #AlloCART

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users